TriangleImmunotherapy (NCT04594187)
Immunotherapy trial for Melanoma (NCT04594187). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with high-risk melanoma found in sentinel lymph nodes, no distant spread, and planned postoperative immunotherapy. Complete dissection of the affected node basin must not have occurred.
The idea: patients are randomized to immunotherapy alone or with radiation to lymph nodes. Radiation totals thirty gray in five treatments over two to two-and-a-half weeks, starting within twelve weeks of biopsy. Researchers test whether it delays regional recurrence and follow patients for five years.
This phase 2 study plans 168 patients. Devarati Mitra leads at MD Anderson; three US sites recruit.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.